Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Impero reports 44% growth in Annual Recurring Revenue for 2021-H1 compared to 2020-H1 in line with IPO strategy plan

Interim financial report for the period January 1, 2021 to June 30, 2021 Highlights from 2021-H1 · Impero increased ARR by 44% in 2021-H1 compared to 2020-H1. ARR for 2021-H1 amounted to DKK 14.2M on June 30, 2021. Impero’s growth is in line with the strategy plan presented in the IPO document. · Impero successfully maintained an uplift of 8% from existing customers. · Impero presented churn below 2%. Impero maintains expectations for Annual Recurring Revenue for the entire year of 2021, expecting ARR at the level of DKK 18-19.5M, as announced in the IPO document.

BioStock: Elicera Therapeutics comes out of the gate running in Q2

For Swedish immuno-oncology company Elicera Therapeutics, the highlight of Q2 was going public and being listed on Nasdaq First North Growth Market, all while raking in more than 60 MSEK in a share issue. The events came as the company had reached new heights with its development pipeline and technology platform, iTANK.Read the article at biostock.se: https://www.biostock.se/en/2021/08/elicera-therapeutics-comes-out-of-the-gate-running-in-q2/ This is a press release from BioStock - Connecting Innovation & Capital.https://www.biostock.se

Medivir receives regulatory approval from MHRA for phase 1/2a combination study with MIV-818

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the company has received regulatory approval from the British Medicines & Healthcare products Regulatory Agency (MHRA) for its upcoming phase 1/2a combination study with the company's leading candidate drug MIV-818 against liver cancer. In the study, MIV-818 will be administered in two combinations, either with lenvatinib, a tyrosine kinase inhibitor or pembrolizumab, an anti-PD-1 check-point inhibitor. The planned trial will be an open-label, multi-center phase 1/2a study starting with a dose escalation part to

Atlas Copco has acquired a German company specialized in positioning technology

Nacka, Sweden, August 31, 2021: Atlas Copco has acquired the assets of NATEV GmbH. The company was founded in 2010 and specializes in position solutions for assembly tools used in industrial production.NATEV has ten employees and is located in Borken, in north-western Germany. In 2019, the company’s sales amounted to approximately 1 MEUR (10.4 MSEK) and in 2020 approximately MEUR 0.5 (MSEK 5.2) NATEV develops systems for real-time positioning and imaging solutions in close cooperation with key customers in the automotive industry. Products include hardware and software used to monitor

Interim report January – June 2021

The period in summary First half year January 1 – June 30, 2021 · On June 17th the Committee for Medicinal Products for Veterinary Use (CVMP) at the European Medicines Agency (EMA) adopted a positive opinion, recommending approval of Strangvac within the EU. · On April 12th Intervacc announced an exclusive distribution agreement with Dechra Pharmaceuticals PLC, to commercialize Intervacc’s leading vaccine candidate Strangvac in Europe, excluding the Nordic and Baltic countries where Intervacc will market and sell Strangvac directly. · The study "Globetrotting strangles: the

Biosergen publishes interim report for the second quarter 2021

Tuesday, August 31, 2021: Biosergen AB (“Biosergen” or the “Company”) thereby publishes the interim report for the second quarter 2021. The interim report is available as an attached document and on the company website (www.biosergen.net)Biosergen AB was registered in February 2021. On April 16, 2021, the company acquired Biosergen AS with the subsidiary Select Pharma PTY LTD and formed the group with Biosergen AB as parent company. As the company is new there are no comparative figures. Summary of the Interim Report for Q2 2021 Consolidated group evenue

Change in number of shares and votes in Evolution AB (publ)

During August, warrants of series 2018/2021 have been exercised to subscribe for 5,735 shares in Evolution AB (publ). As of 31 August 2021, following the exercise of warrants set out above, the number of shares and votes in Evolution AB (publ) amounts to 215,111,115.   For further information, please contact: Jacob Kaplan, CFO, ir@evolution.com.   This information is such that Evolution AB (publ) is obliged to publish according to the Swedish Financial Instruments Trading Act. This press release was submitted for publication by the person above on 31 August 2021 at 08:30

Interim Financial Report – Half year of 2021 (H1 2021)

SGL International A/S (SGL Group – formerly SGL TransGroup International A/S) has today published its Interim Financial Report for the first half year of 2021 (H1 2021). SGL Group (SGL International A/S) · For SGL Group, the H1 2021 revenue was DKK 3,757m versus DKK 2,511m in H1 2020; corresponding to growth of 50% driven by an overall increase of activities for Air and Ocean in Nordics and Asia Pacific and an increase in freight rates globally. · The total Gross Profit was DKK 539m; equivalent to a Gross Margin of 14.4%. · The H1 2021 EBITDA before special items and excluding

Cary Group reports strong growth and further acquisitions during the second quarter

Cary Group, a leading European vehicle glass repair and replacement service provider, today presents selected information on the company's financial and operational development for the second quarter of 2021.Anders Jensen, CEO of Cary Group, comments:”In the second quarter, demand picked up again in our key markets, following an easing of Covid-19 related lock-down measures, and Cary Group was able to deliver strong growth of 40%. Our M&A journey continued with the acquisition of Quick Car Fix in Norway, specialising in SMART repair (Small to Medium Area Repair Techniques). In total, we

WindowMaster realized record high growth in orders and sales in 2021-H1

Company Announcement No. 16-2021 – Inside Information Copenhagen, August 31, 2021Highlights from 2021-H1 WindowMaster realized strong sales growth in the 1[st] half of 2021 – with high activity in all markets – despite continued COVID-19 constraints, Brexit etc. Both order intake and turnover reached an all-time high. · Net sales for 2021-H1 ended at 107m DKK including the acquisition of Climatic A/S representing a 21.7% increase compared to 2020-1H. Under this positive development lies further – not yet accounted for – postponed turnover of 2m DKK caused by supply chain delays

Eurocine Vaccines discloses year-end report for the fiscal year 2020/2021

Eurocine Vaccines AB (“Eurocine Vaccines”) hereby discloses the year-end report for the fiscal year 2020/2021. Below is a summary of the report. The full report is available on Eurocine Vaccines’ website and as an attachment. 2021-04-01– 2021-06-30 (fourth quarter) · Profit after tax for the quarter amounted to -6.0 MSEK (-2.5 MSEK) · Income for the quarter amounted to 2 KSEK (0 KSEK) · Earnings per share for the quarter amounted to SEK -0.768 (SEK -0.479) * 2020-07-01– 2021-06-30 (fiscal year, twelve months) · Profit after tax for

Olvi confirms acquisition of Danish brewing company Bryggeriet Vestfyen

Olvi plc                                 Stock Exchange Release 31 August 2021 at 9:00 am Olvi confirms acquisition of Danish brewing company Bryggeriet Vestfyen Olvi confirms acquisition of Danish brewing company Bryggeriet Vestfyen. The acquisition will be completed according to the previously announced schedule. On May 12, 2021, Olvi plc announced a conditional acquisition agreement in a stock exchange release. The main condition for the completion of the acquisition was that Olvi would be able to increase its holding to 90 percent. The acquisition is confirmed with a 96.8

Axel Johnson International grows its service offering in fluid handlings solutions in Switzerland

AxFlow Germany, part of AxFlow, the Fluid Handling Solutions business group of Axel Johnson International, grows its service business in Switzerland through the acquisition of Ateliers Ehrismann SA.“The acquisition of Ateliers Ehrismann will make a great addition to AxFlow and is in line with our business group strategy to continue to expand our service business,” says Ole Weiner, CEO of AxFlow Holding. Founded in 1923, Ateliers Ehrismann SA is a Geneva-based company active in the service of electric motors, pumps and other electrical and mechanical machinery. Ateliers Ehrismann SA also

Arcus: Last day of trading and listing today

THIS STOCK EXCHANGE RELEASE MAY NOT BE PUBLISHED OR DISTRIBUTED, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION WOULD VIOLATE APPLICABLE LAWS OR RULES OR WOULD REQUIRE ADDITIONAL DOCUMENTS TO BE COMPLETED OR REGISTERED OR REQUIRE ANY MEASURE TO BE UNDERTAKEN IN ADDITION TO THE REQUIREMENTS UNDER FINNISH LAW. FOR FURTHER INFORMATION, SEE “IMPORTANT NOTICE” BELOW. Arcus: Last day of trading and listing today Reference is made to the stock exchange announcement on

Bactiguard recruits Chief Licensing Officer to accelerate growth

Carl Johan Fredin, with many years of international experience from leading companies and positions in pharmaceuticals, MedTech and healthcare, has been recruited to a new role as Chief Licensing Officer. Carl Johan, whose most recent position was with Mölnlycke, will take up his new role on 1 October and report to the CEO.“The interest in Bactiguard’s technology is clearly increasing and our ambition is to accelerate the development of new license agreements and innovative applications for infection prevention together with our partners. To do so we need to strengthen our team”, says

Number of shares and votes in Calliditas Therapeutics

During August, the number of shares and votes in Calliditas Therapeutics AB (publ) has increased due to the directed share issue of 2,400,000 new shares that the company carried out on August 12, 2021. Thus, as of August 31, 2021, the number of shares and votes in the company amounts to 52,341,584. For further information, please contact: Mikael Widell, Investor relations Tel.: +46 703 11 99 60, email: mikael.widell@calliditas.com The information in the press release is such that Calliditas Therapeutics AB (publ) is required to disclose pursuant to the Swedish Financial

Hansa Biopharma announces participation in Fall investor conferences and provides updated financial calendar

Hansa Biopharma to participate in several leading global healthcare conferences in SeptemberLund, Sweden August 31, 2021 Hansa Biopharma AB “Hansa”, (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, today announced that the Company’s management team will present at the following upcoming investor conferences during September 2021: · Erik Penser Access Minibolags dag, Malmö Tuesday August 31, 2021 at 17:15 (CET) · Pareto Securities Health Care Conference on Thursday September 2 2021, at 13:10 (CET) · Redburn Gene Therapy Virtual Summit

New number of shares and votes in Corem

As a result of Corem Property Group AB (publ)’s (“Corem”) public takeover bid to the shareholders of Klövern AB (publ), the total number of shares and votes in Corem has changed. During August new issue was made of 2,092,531 ordinary shares of Class A, 29,311,525 ordinary shares of Class B, 367,847 ordinary shares of Class D and 528,991 preference shares. As of today's date, the total number of shares in Corem thus amounts to 94,703,126 ordinary shares of Class A, 1,022,619,051 ordinary shares of Class B, 7,545,809 ordinary shares of Class D and 12,415,295 preference shares. Each

Hemsö acquires nursing home in Germany

Hemsö has acquired a nursing home in Steinfurt in North Rhine-Westphalia, Germany. The investment amount is EUR 11.9 million.Hemsö has acquired a nursing home in Greven in the district of Steinfurt in North Rhine-Westphalia in Germany. The nursing home was built in 2007, has 80 single rooms and a total area of 4,150 sqm. The property has been leased to CMS Senioren-Residenzen (Alloheim Group) under a long-term contract. “In addition to acquisitions of educational properties such as schools and teaching centres, the acquisition of nursing homes is still our core business in Germany. The

Lantmännen acquires 10 percent of Hargs Hamn AB

Lantmännen has acquired 10 percent of Hargs Hamn AB. Since 2019, the port at Hargshamn has become increasingly important for Lantmännens’ grain exports by ship. Hence, the investment underlines the importance of continued investments in the grain value chain.Lantmännen has acquired 10 percent of Hargs Hamn AB. This investment is a clearly stresses the importance of continued investments in the grain value chain and Lantmännen’s long-term commitment to the port. Furthermore, it means a bigger opportunity to influence further development in a positive direction for grain processing. “

Read original

AcadeMedia’s Year-end Report July 2020 – June 2021

Fourth quarter (April – June 2021) · Net sales increased by 13.8 percent and amounted to SEK 3,672 million (3,227). Organic growth, including bolt-on acquisitions and adjusted for currency effects, was 10.4 percent. · Operating profit (EBIT) amounted to SEK 329 million (334). · Adjusted operating profit, adjusted for items affecting comparability and effects of IFRS 16, amounted to SEK 280 million (279). Items affecting comparability amounted to SEK -14 million (0). · Net profit for the period amounted to SEK 180 million (179). · Diluted earnings per share was SEK 1.70 (1.

Bonava sells 50 rental apartments in Helsinki

Bonava is selling 50 rental apartments in Helsinki, Finland, to eQ Residential Fund. The transaction amounts to EUR 12 million and the first housing units are expected to be completed and handed over to the customer in the first quarter of 2023.– We are very happy to continue our cooperation with eQ now in a new residential area in eastern Helsinki. After starting this project, we will have 300 homes in production in the area, and all in all, we plan to build approximately 550 homes. When completed, this neighbourhood with its special brass-shining facades will become a visible landmark in

New Fazer biscuits for the autumn season

Fazer’s new biscuits give great energy and create autumnal moments of indulgence. To celebrate Fazer’s 130th anniversary, the classic Islanti flavour is introduced to chocolate biscuits and the traditional Domino gets a new youthful flavour variant of banana and chocolate. The new products will be available in shops in September and October.Domino Banana Choco 175 gFinns’ favourite biscuit gets a new youthful flavour when the beloved cocoa biscuit is filled with banana and chocolate. This new biscuit is suitable for vegans and made in Finland, which you can tell also by the Key Flag

Ratos AB – change in number of shares and votes

The first opportunity to convert convertible debentures into shares according to the incentive program for the CEO and other key personnel in Ratos decided on by the 2018 Annual General Meeting was completed in August 2021. Through the conversion, the number of Class B shares increased by 557,924 and the number of votes by 55,792.4. After the increase, the share capital amounts to SEK 1,022,801,283. Before the After the conversion, no.conversion,no.Class A 84,637,060 Class A shares: 84,637,060shares:Class B 239,503,836

There are no items matching the current filter
There are no more items matching the current filter
Back to top